Compare $EDIT vs $SPRY | Chartloom

Compare

$EDIT vs $SPRY

Editas Medicine Inc · ARS Pharmaceuticals Inc

EDIT

Editas Medicine Inc

SPRY

ARS Pharmaceuticals Inc

Compare $EDIT vs $SPRY

Comparing Editas Medicine Inc and ARS Pharmaceuticals Inc

EDITEditas Medicine Inc

SPRYARS Pharmaceuticals Inc

EDITEditas Medicine Inc

Market cap

$487M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

27.22x

Rev growth (TTM)

20.8%

YTD performance

41.5%

52W performance

-30.1%

FCF yield

-24.8%

SPRYARS Pharmaceuticals Inc

Market cap

$420M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.81x

Rev growth (TTM)

4.1%

YTD performance

-63.2%

52W performance

-61.9%

FCF yield

-46.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

EDIT

SPRY

Detailed metrics comparison

EDIT

Editas Medicine Inc

SPRY

ARS Pharmaceuticals Inc

Market Cap

EDIT$487M

SPRY$420M

Enterprise Value

EDIT$361M

SPRY$509M

Price

EDIT$2.90

SPRY$4.23

P/E Ratio

EDITN/A

SPRYN/A

P/S Ratio

EDIT10.35x

SPRY3.59x

EV/Sales

EDIT7.67x

SPRY4.35x

EV/EBITDA

EDIT0.00x

SPRY0.00x

P/B Ratio

EDIT3.82x

SPRY32.35x

P/FCF Ratio

EDITN/A

SPRYN/A

EV/FCF

EDIT-2.99x

SPRY-2.59x

PEG Ratio

EDITN/A

SPRYN/A

Forward P/E (NTM)

EDITN/A

SPRYN/A

Forward P/S (NTM)

EDIT27.22x

SPRY2.81x

Revenue (TTM)

EDIT$47M

SPRY$117M

Revenue Growth (YoY)

EDIT20.8%

SPRY4.1%

Forward Rev Growth

EDIT-18.4%

SPRY46.9%

Gross Margin (TTM)

EDIT0.0%

SPRY71.4%

Operating Margin (TTM)

EDIT0.0%

SPRY0.0%

EBITDA Margin (TTM)

EDIT-172.4%

SPRY-183.6%

Net Margin (TTM)

EDIT-157.3%

SPRY-184.2%

FCF Margin (TTM)

EDIT-256.5%

SPRY-168.1%

Net Income (TTM)

EDIT$-74M

SPRY$-215M

FCF (TTM)

EDIT$-121M

SPRY$-197M

EPS (TTM)

EDIT-$0.62

SPRY-$2.17

ROE (TTM)

EDIT-19663.0%

SPRY-25667.0%

ROA (TTM)

EDIT-3817.0%

SPRY-6963.0%

ROIC (TTM)

EDIT-7815.0%

SPRY-11943.0%

Cash

EDIT$182M

SPRY$8M

Debt

EDIT$56M

SPRY$97M

Net Cash/Debt

EDIT$126M

SPRY$-89M

Current Ratio (TTM)

EDIT3.19x

SPRY3.48x

Quick Ratio (TTM)

EDIT3.13x

SPRY3.13x

Debt/Equity (TTM)

EDIT0.53x

SPRY7.73x

Debt/Assets (TTM)

EDIT0.0%

SPRY0.0%

Interest Coverage (TTM)

EDITN/A

SPRYN/A

Net Debt/EBITDA (TTM)

EDIT0.00x

SPRY0.00x

Beta

EDIT2.12

SPRY0.92

52W Performance

EDIT-30.1%

SPRY-61.9%

YTD Performance

EDIT41.5%

SPRY-63.2%

% from 52W High

EDIT-33.0%

SPRY-67.8%

% from 52W Low

EDIT74.7%

SPRY6.1%

Asset Turnover (TTM)

EDIT0.24x

SPRY0.38x

FCF Yield (TTM)

EDIT-24.8%

SPRY-46.8%

Earnings Yield (TTM)

EDIT-15.2%

SPRY-51.3%

Dividend Yield (TTM)

EDITN/A

SPRYN/A

Rule of 40

EDIT-235.6

SPRY-164.1

EV/GP/RG

EDITN/A

SPRY0.16

Ticker research

View EDIT research View SPRY research

Metric	EDIT Editas Medicine Inc	SPRY ARS Pharmaceuticals Inc
Market & Valuation
Market Cap	$487M	$420M
Enterprise Value	$361M	$509M
Price	$2.90	$4.23
P/E Ratio	N/A	N/A
P/S Ratio	10.35x	3.59x
EV/Sales	7.67x	4.35x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.82x	32.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.99x	-2.59x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	27.22x	2.81x
Revenue & Growth
Revenue (TTM)	$47M	$117M
Revenue Growth (YoY)	20.8%	4.1%
Forward Rev Growth	-18.4%	46.9%
Profitability
Gross Margin (TTM)	0.0%	71.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-172.4%	-183.6%
Net Margin (TTM)	-157.3%	-184.2%
FCF Margin (TTM)	-256.5%	-168.1%
Net Income (TTM)	$-74M	$-215M
FCF (TTM)	$-121M	$-197M
EPS (TTM)	-$0.62	-$2.17
ROE (TTM)	-19663.0%	-25667.0%
ROA (TTM)	-3817.0%	-6963.0%
ROIC (TTM)	-7815.0%	-11943.0%
Financial Health
Cash	$182M	$8M
Debt	$56M	$97M
Net Cash/Debt	$126M	$-89M
Current Ratio (TTM)	3.19x	3.48x
Quick Ratio (TTM)	3.13x	3.13x
Debt/Equity (TTM)	0.53x	7.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.12	0.92
52W Performance	-30.1%	-61.9%
YTD Performance	41.5%	-63.2%
% from 52W High	-33.0%	-67.8%
% from 52W Low	74.7%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.24x	0.38x
FCF Yield (TTM)	-24.8%	-46.8%
Earnings Yield (TTM)	-15.2%	-51.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-235.6	-164.1
EV/GP/RG	N/A	0.16
Ticker research	View EDIT research	View SPRY research

Valuation

P/S Ratio

SPRY

3.59x

EDIT

10.35x

EV/FCF

EDIT

-2.99x

SPRY

-2.59x

Growth & revenue

Revenue Growth TTM

EDIT

20.8%

SPRY

4.1%

Forward Revenue Growth

SPRY

46.9%

EDIT

-18.4%

Profitability & performance

Gross Margin

SPRY

71.4%

EDIT

0.0%

ROE

EDIT

-19663.0%

SPRY

-25667.0%

FCF Yield %

EDIT

-24.8%

SPRY

-46.8%

52-Week Performance

EDIT

-30.1%

SPRY

-61.9%

Detailed metrics comparison

EDIT

Editas Medicine Inc

SPRY

ARS Pharmaceuticals Inc

Market Cap

EDIT$487M

SPRY$420M

Enterprise Value

EDIT$361M

SPRY$509M

Price

EDIT$2.90

SPRY$4.23

P/E Ratio

EDITN/A

SPRYN/A

P/S Ratio

EDIT10.35x

SPRY3.59x

EV/Sales

EDIT7.67x

SPRY4.35x

EV/EBITDA

EDIT0.00x

SPRY0.00x

P/B Ratio

EDIT3.82x

SPRY32.35x

P/FCF Ratio

EDITN/A

SPRYN/A

EV/FCF

EDIT-2.99x

SPRY-2.59x

PEG Ratio

EDITN/A

SPRYN/A

Forward P/E (NTM)

EDITN/A

SPRYN/A

Forward P/S (NTM)

EDIT27.22x

SPRY2.81x

Revenue (TTM)

EDIT$47M

SPRY$117M

Revenue Growth (YoY)

EDIT20.8%

SPRY4.1%

Forward Rev Growth

EDIT-18.4%

SPRY46.9%

Gross Margin (TTM)

EDIT0.0%

SPRY71.4%

Operating Margin (TTM)

EDIT0.0%

SPRY0.0%

EBITDA Margin (TTM)

EDIT-172.4%

SPRY-183.6%

Net Margin (TTM)

EDIT-157.3%

SPRY-184.2%

FCF Margin (TTM)

EDIT-256.5%

SPRY-168.1%

Net Income (TTM)

EDIT$-74M

SPRY$-215M

FCF (TTM)

EDIT$-121M

SPRY$-197M

EPS (TTM)

EDIT-$0.62

SPRY-$2.17

ROE (TTM)

EDIT-19663.0%

SPRY-25667.0%

ROA (TTM)

EDIT-3817.0%

SPRY-6963.0%

ROIC (TTM)

EDIT-7815.0%

SPRY-11943.0%

Cash

EDIT$182M

SPRY$8M

Debt

EDIT$56M

SPRY$97M

Net Cash/Debt

EDIT$126M

SPRY$-89M

Current Ratio (TTM)

EDIT3.19x

SPRY3.48x

Quick Ratio (TTM)

EDIT3.13x

SPRY3.13x

Debt/Equity (TTM)

EDIT0.53x

SPRY7.73x

Debt/Assets (TTM)

EDIT0.0%

SPRY0.0%

Interest Coverage (TTM)

EDITN/A

SPRYN/A

Net Debt/EBITDA (TTM)

EDIT0.00x

SPRY0.00x

Beta

EDIT2.12

SPRY0.92

52W Performance

EDIT-30.1%

SPRY-61.9%

YTD Performance

EDIT41.5%

SPRY-63.2%

% from 52W High

EDIT-33.0%

SPRY-67.8%

% from 52W Low

EDIT74.7%

SPRY6.1%

Asset Turnover (TTM)

EDIT0.24x

SPRY0.38x

FCF Yield (TTM)

EDIT-24.8%

SPRY-46.8%

Earnings Yield (TTM)

EDIT-15.2%

SPRY-51.3%

Dividend Yield (TTM)

EDITN/A

SPRYN/A

Rule of 40

EDIT-235.6

SPRY-164.1

EV/GP/RG

EDITN/A

SPRY0.16

Ticker research

View EDIT research View SPRY research

Metric	EDIT Editas Medicine Inc	SPRY ARS Pharmaceuticals Inc
Market & Valuation
Market Cap	$487M	$420M
Enterprise Value	$361M	$509M
Price	$2.90	$4.23
P/E Ratio	N/A	N/A
P/S Ratio	10.35x	3.59x
EV/Sales	7.67x	4.35x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.82x	32.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.99x	-2.59x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	27.22x	2.81x
Revenue & Growth
Revenue (TTM)	$47M	$117M
Revenue Growth (YoY)	20.8%	4.1%
Forward Rev Growth	-18.4%	46.9%
Profitability
Gross Margin (TTM)	0.0%	71.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-172.4%	-183.6%
Net Margin (TTM)	-157.3%	-184.2%
FCF Margin (TTM)	-256.5%	-168.1%
Net Income (TTM)	$-74M	$-215M
FCF (TTM)	$-121M	$-197M
EPS (TTM)	-$0.62	-$2.17
ROE (TTM)	-19663.0%	-25667.0%
ROA (TTM)	-3817.0%	-6963.0%
ROIC (TTM)	-7815.0%	-11943.0%
Financial Health
Cash	$182M	$8M
Debt	$56M	$97M
Net Cash/Debt	$126M	$-89M
Current Ratio (TTM)	3.19x	3.48x
Quick Ratio (TTM)	3.13x	3.13x
Debt/Equity (TTM)	0.53x	7.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.12	0.92
52W Performance	-30.1%	-61.9%
YTD Performance	41.5%	-63.2%
% from 52W High	-33.0%	-67.8%
% from 52W Low	74.7%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.24x	0.38x
FCF Yield (TTM)	-24.8%	-46.8%
Earnings Yield (TTM)	-15.2%	-51.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-235.6	-164.1
EV/GP/RG	N/A	0.16
Ticker research	View EDIT research	View SPRY research